List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8593232/publications.pdf Version: 2024-02-01



ALESSANDDA EVA

#	Article	IF	CITATIONS
1	Targeting of Ubiquitin E3 Ligase RNF5 as a Novel Therapeutic Strategy in Neuroectodermal Tumors. Cancers, 2022, 14, 1802.	1.7	4
2	Exosomal MicroRNAs as Potential Biomarkers of Hepatic Injury and Kidney Disease in Glycogen Storage Disease Type Ia Patients. International Journal of Molecular Sciences, 2022, 23, 328.	1.8	5
3	Multiparametric flow cytometry highlights B7-H3 as a novel diagnostic/therapeutic target in GD2neg/low neuroblastoma variants. , 2021, 9, e002293.		25
4	MO036DAPAGLIFLOZIN RESCUES THE RENAL PHENOTYPE OF GLYCOGEN STORAGE DISEASE TYPE IB. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
5	Connectivity Map Analysis Indicates PI3K/Akt/mTOR Inhibitors as Potential Anti-Hypoxia Drugs in Neuroblastoma. Cancers, 2021, 13, 2809.	1.7	10
6	The SGLT2-inhibitor dapagliflozin improves neutropenia and neutrophil dysfunction in a mouse model of the inherited metabolic disorder GSDIb. Molecular Genetics and Metabolism Reports, 2021, 29, 100813.	0.4	4
7	MYC regulates metabolism through vesicular transfer of glycolytic kinases. Open Biology, 2021, 11, 210276.	1.5	5
8	The SRCIN1/p140Cap adaptor protein negatively regulates the aggressiveness of neuroblastoma. Cell Death and Differentiation, 2020, 27, 790-807.	5.0	25
9	Transcriptome analysis defines myocardium gene signatures in children with ToF and ASD and reveals disease-specific molecular reprogramming in response to surgery with cardiopulmonary bypass. Journal of Translational Medicine, 2020, 18, 21.	1.8	11
10	MCM2 and Carbonic Anhydrase 9 Are Novel Potential Targets for Neuroblastoma Pharmacological Treatment. Biomedicines, 2020, 8, 471.	1.4	9
11	Hypoxia Predicts Poor Prognosis in Neuroblastoma Patients and Associates with Biological Mechanisms Involved in Telomerase Activation and Tumor Microenvironment Reprogramming. Cancers, 2020, 12, 2343.	1.7	36
12	Circulating exosomal microRNA as potential biomarkers of hepatic injury and inflammation inGlycogen storage disease type 1a. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	8
13	Secondary Somatic Mutations in G-Protein-Related Pathways and Mutation Signatures in Uveal Melanoma. Cancers, 2019, 11, 1688.	1.7	20
14	Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study. Cancers, 2019, 11, 1476.	1.7	43
15	A Proteomic Analysis of GSD-1a in Mouse Livers: Evidence for Metabolic Reprogramming, Inflammation, and Macrophage Polarization. Journal of Proteome Research, 2019, 18, 2965-2978.	1.8	8
16	Characterization of high- and low-risk hepatocellular adenomas by magnetic resonance in an animal model of glycogen storage disease type 1A. DMM Disease Models and Mechanisms, 2019, 12, .	1.2	4
17	PIPE-T: a new Galaxy tool for the analysis of RT-qPCR expression data. Scientific Reports, 2019, 9, 17550.	1.6	12
18	Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration. Frontiers in Immunology, 2018, 9, 2358.	2.2	104

#	Article	IF	CITATIONS
19	Development and characterization of an inducible mouse model for glycogen storage disease type Ib. Journal of Inherited Metabolic Disease, 2018, 41, 1015-1025.	1.7	6
20	<i>CHL1</i> gene acts as a tumor suppressor in human neuroblastoma. Oncotarget, 2018, 9, 25903-25921.	0.8	24
21	Regulation of Human Macrophage M1–M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1. Frontiers in Immunology, 2017, 8, 1097.	2.2	208
22	Immunohistochemical analysis of PDK1, PHD3 and HIF-1α expression defines the hypoxic status of neuroblastoma tumors. PLoS ONE, 2017, 12, e0187206.	1.1	10
23	Artificial neural network classifier predicts neuroblastoma patients' outcome. BMC Bioinformatics, 2016, 17, 347.	1.2	32
24	Regulation of Langerhans cell functions in a hypoxic environment. Journal of Molecular Medicine, 2016, 94, 943-955.	1.7	10
25	Dbl oncogene expression in MCF-10 A epithelial cells disrupts mammary acinar architecture, induces EMT and angiogenic factor secretion. Cell Cycle, 2015, 14, 1426-1437.	1.3	2
26	Identification of CD300a as a new hypoxia-inducible gene and a regulator of CCL20 and VEGF production by human monocytes and macrophages. Innate Immunity, 2014, 20, 721-734.	1.1	23
27	Development of hepatocellular adenomas and carcinomas in mice with liver-specific G6Pase-α deficiency. DMM Disease Models and Mechanisms, 2014, 7, 1083-1091.	1.2	20
28	Identification of a novel mouse Dbl proto-oncogene splice variant: Evidence that SEC14 domain is involved in GEF activity regulation. Gene, 2014, 537, 220-229.	1.0	6
29	Chronic hypoxia reprograms human immature dendritic cells by inducing a proinflammatory phenotype and <scp>TREM</scp> â€I expression. European Journal of Immunology, 2013, 43, 949-966.	1.6	49
30	Logic Learning Machine creates explicit and stable rules stratifying neuroblastoma patients. BMC Bioinformatics, 2013, 14, S12.	1.2	20
31	The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cells. Immunobiology, 2013, 218, 76-89.	0.8	59
32	Bradykinin-induced asthmatic fibroblast/myofibroblast activities via bradykinin B2 receptor and different MAPK pathways. European Journal of Pharmacology, 2013, 710, 100-109.	1.7	26
33	Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome. BMC Bioinformatics, 2012, 13, S13.	1.2	15
34	Generation of explicit rules predicting neuroblastoma patients' outcome. EMBnet Journal, 2012, 18, 92.	0.2	0
35	Treatment of newborn G6pc mice with bone marrow-derived myelomonocytes induces liver repair. Journal of Hepatology, 2011, 55, 1263-1271.	1.8	8
36	Hypoxia modulates the gene expression profile of immunoregulatory receptors in human mature dendritic cells: identification of TREM-1 as a novel hypoxic marker in vitro and in vivo. Blood, 2011, 117, 2625-2639.	0.6	119

#	Article	IF	CITATIONS
37	High frequency of development of B cell lymphoproliferation and diffuse large B cell lymphoma in Dbl knock-in mice. Journal of Molecular Medicine, 2011, 89, 493-504.	1.7	6
38	The Tumor Suppressor Hamartin Enhances Dbl Protein Transforming Activity through Interaction with Ezrin. Journal of Biological Chemistry, 2011, 286, 29973-29983.	1.6	10
39	Mechanisms of bradykinin-induced contraction in human fetal lung fibroblasts. European Respiratory Journal, 2010, 36, 655-664.	3.1	15
40	p130Cas is an essential transducer element in ErbB2 transformation. FASEB Journal, 2010, 24, 3796-3808.	0.2	49
41	A biology-driven approach identifies the hypoxia gene signature as a predictor of the outcome of neuroblastoma patients. Molecular Cancer, 2010, 9, 185.	7.9	85
42	Induction of Epithelial Mesenchimal Transition and Vasculogenesis in the Lenses of Dbl Oncogene Transgenic Mice. PLoS ONE, 2009, 4, e7058.	1.1	3
43	Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. Journal of Leukocyte Biology, 2008, 84, 1472-1482.	1.5	88
44	Transcriptome of Hypoxic Immature Dendritic Cells: Modulation of Chemokine/Receptor Expression. Molecular Cancer Research, 2008, 6, 175-185.	1.5	94
45	Gα13 Regulation of Proto-Dbl Signaling. Cell Cycle, 2007, 6, 2058-2070.	1.3	13
46	Recruitment of Dbl by Ezrin and Dystroglycan Drives Membrane Proximal Cdc42 Activation and Filopodia Formation. Cell Cycle, 2007, 6, 353-363.	1.3	47
47	Induction of Macrophage Glutamine: Fructose-6-Phosphate Amidotransferase Expression by Hypoxia and by Picolinic Acid. International Journal of Immunopathology and Pharmacology, 2007, 20, 47-58.	1.0	33
48	Growth Arrest-Inducing Genes Are Activated in Dbl-Transformed Mouse Fibroblasts. Gene Expression, 2006, 13, 155-165.	0.5	1
49	Inhibition of PI3K induces Rac Activation and Membrane Ruffling in Proto-Dbl Expressing Cells. Cell Cycle, 2006, 5, 2657-2665.	1.3	5
50	Newborn liver gene transfer by an HIV-2-based lentiviral vector. Gene Therapy, 2005, 12, 803-814.	2.3	13
51	Constitutively Active Cdc42 Mutant Confers Growth Disadvantage in Cell Transformation. Cell Cycle, 2005, 4, 1675-1682.	1.3	24
52	Phosphorylation-independent membrane relocalization of ezrin following association with Dbl in vivo. Oncogene, 2004, 23, 4098-4106.	2.6	20
53	Defective Dendrite Elongation but Normal Fertility in Mice Lacking the Rho-Like GTPase Activator Dbl. Molecular and Cellular Biology, 2002, 22, 3140-3148.	1.1	31
54	Regulation of Proto-Dbl by Intracellular Membrane Targeting and Protein Stability. Journal of Biological Chemistry, 2002, 277, 19745-19753.	1.6	30

#	Article	IF	CITATIONS
55	The integrin cytoplasmic domain-associated protein ICAP-1 binds and regulates Rho family GTPases during cell spreading. Journal of Cell Biology, 2002, 156, 377-388.	2.3	58
56	Modulation of Oncogenic DBL Activity by Phosphoinositol Phosphate Binding to Pleckstrin Homology Domain. Journal of Biological Chemistry, 2001, 276, 19524-19531.	1.6	68
57	Autoinhibition Mechanism of Proto-Dbl. Molecular and Cellular Biology, 2001, 21, 1463-1474.	1.1	72
58	Distinct involvement of Cdc42 and RhoA GTPases in actin organization and cell shape in untransformed and Dbl oncogene transformed NIH3T3 cells. Oncogene, 2000, 19, 1428-1436.	2.6	25
59	Human dbl proto-oncogene in 85 kb of Xq26, and determination of the transcription initiation site. Gene, 2000, 253, 107-115.	1.0	3
60	Actin cytoskeleton polymerization in Dbl-transformed NIH3T3 fibroblasts is dependent on cell adhesion to specific extracellular matrix proteins. Oncogene, 1997, 14, 1933-1943.	2.6	19
61	The Pleckstrin Homology Domain Mediates Transformation by Oncogenic Dbl through Specific Intracellular Targeting. Journal of Biological Chemistry, 1996, 271, 19017-19020.	1.6	117
62	[38] Cell transformation by dbl oncogene. Methods in Enzymology, 1995, 256, 347-358.	0.4	6
63	Cellular transformation and guanine nucleotide exchange activity are catalyzed by a common domain on the dbl oncogene product. Journal of Biological Chemistry, 1994, 269, 62-5.	1.6	258
64	Oncogene ect2 is related to regulators of small GTP-binding proteins. Nature, 1993, 362, 462-465.	13.7	281
65	Use of transgenic mice in the study of proto-oncogene functions. Seminars in Cell Biology, 1992, 3, 137-145.	3.5	3
66	Catalysis of guanine nucleotide exchange on the CDC42Hs protein by the dbloncogene product. Nature, 1991, 354, 311-314.	13.7	437
67	Chromosomal localization of DBL oncogene sequences. Genomics, 1989, 5, 546-553.	1.3	10
68	Detection of activated proto-oncogenes in N-nitrosodiethylamine-induced liver tumors: a comparison between B6C3F1 mice and Fischer 344 rats. Carcinogenesis, 1988, 9, 271-276.	1.3	108
69	The predicted DBL oncogene product defines a distinct class of transforming proteins Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 2061-2065.	3.3	60
70	Interactions of Retroviral and Cellular Transforming Genes with Hematopoietic Cells. Annals of the New York Academy of Sciences, 1987, 511, 148-170.	1.8	4
71	Identification of the protein encoded by the human diffuse B-cell lymphoma (dbl) oncogene Proceedings of the National Academy of Sciences of the United States of America, 1986, 83, 8868-8872.	3.3	33
72	High frequency of c-K-ras activation in 3-methylcholanthrene-induced mouse thymomas. Carcinogenesis, 1986, 7, 1931-1933.	1.3	14

#	Article	IF	CITATIONS
73	2 Interactions of Oncogenes with Haematopoietic Cells. Clinics in Haematology, 1986, 15, 573-596.	2.2	15
74	Isolation of a new human oncogene from a diffuse B-cell lymphoma. Nature, 1985, 316, 273-275.	13.7	205
75	ONCOGENE RESEARCH: CLOSING IN ON A BETTER UNDERSTANDING OF CANCER CAUSATION. Annals of the New York Academy of Sciences, 1984, 437, 150-160.	1.8	0
76	Frequent activation of c-kis as a transforming gene in fibrosarcomas induced by methylcholanthrene. Science, 1983, 220, 955-956.	6.0	103
77	Transforming genes of human hematopoietic tumors: frequent detection of ras-related oncogenes whose activation appears to be independent of tumor phenotype Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 4926-4930.	3.3	166
78	Expression of cellular homologues of retroviral onc genes in human hematopoietic cells Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 2490-2494.	3.3	556
79	Differential expression of the amv gene in human hematopoietic cells Proceedings of the National Academy of Sciences of the United States of America, 1982, 79, 2194-2198.	3.3	413
80	Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells. Nature, 1982, 295, 116-119.	13.7	514
81	Microsystem to Evaluate the Incorporation of3H-Uridine in Macrophage RNA. Immunological Investigations, 1981, 10, 577-589.	0.9	3
82	A microsystem to evaluate the synthesis of [3H]leucine labeled proteins by macrophages. Journal of Immunological Methods, 1980, 33, 231-238.	0.6	3
83	A microsystem to evaluate the synthesis of [3H]leucine labeled proteins by macrophages. Journal of Immunological Methods, 1980, 33, 231-238.	0.6	7
84	Untargeted LC-HRMS Based-Plasma Metabolomics Reveals 3-O-Methyldopa as a New Biomarker of Poor Prognosis in High-Risk Neuroblastoma. Frontiers in Oncology, 0, 12, .	1.3	2